论文部分内容阅读
自１９８５年１月～１９９３年１月共收治９８例小细胞肺癌颅内转移患者，按治疗方法不同，分为单纯化疗组（Ａ组）、单纯放疗组（Ｂ组）、综合治疗组（Ｃ组）、Ａ组３０例、Ｂ组３２例、Ｃ组３６例。Ａ、Ｂ、Ｃ各组的１、２年生存率及中位生存期分别为：Ａ组０、０、３．２个月，Ｂ组２５％、９．４％、６．５个月，Ｃ组３０．５％、１９．４％、９．６个月，Ｂ、Ｃ两组的１、２年生存率及中位生存期明显高于Ａ组。Ａ、Ｂ、Ｃ组单发转移灶中位生存期分别为３．４、７．２、１０．８个月，多发转移灶中位生存期分别为２．６、５．８、８．４个月。３组肺内原发灶控制患者中位生存期分别为４．４、７、１２个月，肺内原发灶未控制患者中位生存期分别为２．６、５．８、９．２个月。如何提高肺部原发灶控制率，提高小细胞肺癌颅内转移疗效，仍需进一步探讨，作者认为，在小细胞肺癌的综合治疗中，只要病人条件允许，全脑预防照射是有积极意义的，可否提高生存率，应作随机分组临床研究。
From January 1985 to January 1993, a total of 98 patients with intracranial small cell lung cancer were treated. According to different treatment methods, they were divided into chemotherapy alone group (A group), radiotherapy alone group (B group), comprehensive treatment group (C Group), group A 30 cases, group B 32 cases, group C 36 cases. The 1-, 2-year survival rates and median survival time for each group of A, B, and C were 0, 0, and 3.2 months for group A, and 25%, 9.4%, and 6.5 months for group B, respectively. In group C, 30.5%, 19.4%, and 9.6 months, the 1-year and 2-year survival rates and median survival time in groups B and C were significantly higher than those in group A. The median survival of single metastases in groups A, B, and C was 3.4, 7.2, and 10.8 months, respectively, and the median survival time for multiple metastases was 2.6, 5.8, and 8.4, respectively. Months. The median survival time of the three groups of primary lung control patients was 4.4, 7, and 12 months, respectively, and the median survival time of patients with uncontrolled primary lung tumors was 2.6, 5.8, and 9.2, respectively. Months. How to improve the control rate of primary foci in the lung and improve the curative effect of intracranial metastasis of small cell lung cancer still needs further investigation. The authors believe that in the comprehensive treatment of small cell lung cancer, as long as the patient conditions allow, the whole brain to prevent irradiation is of positive significance. Whether the survival rate can be improved should be randomized into clinical studies.